A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment

被引:4
作者
Bays, Harold E. [1 ]
机构
[1] Louisville Metab & Atherosclerosis Res Ctr Inc, 3288 Illinois Ave, Louisville, KY 40213 USA
关键词
Low-density lipoprotein cholesterol; Guidelines; Lipid goals; Recommendations; Cardiovascular disease risk assessments; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; NON-HDL CHOLESTEROL; 2013 ACC/AHA GUIDELINE; CARDIOVASCULAR-DISEASE; APOLIPOPROTEIN-B; FAMILIAL HYPERCHOLESTEROLEMIA; SERUM-CHOLESTEROL; AMERICAN-COLLEGE; LDL CHOLESTEROL;
D O I
10.1016/j.jacl.2015.10.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Having knowledge of worldwide lipid guidelines and recommendations may provide clinicians a more global perspective on lipid management. This perspective reviews 8 international scientific and/or medical organizations' lipid guidelines, recommendations, and position papers: the National Lipid Association (2014), National Institute for Health and Care Excellence (2014), International Atherosclerosis Society (2013), American College of Cardiology/American Heart Association (2013), Canadian Cardiovascular Society (2013), Japan Atherosclerosis Society (2012), European Society of Cardiology/European Atherosclerosis Society (2012), and Adult Treatment Panel III (2001/2004). Part 1 of this perspective focuses on sentinel components of these lipid guidelines and recommendations as applied to the role of atherogenic lipoprotein cholesterol levels, primary lipid target of therapy, other primary and secondary lipid treatment targets, and assessment of atherosclerotic cardiovascular disease (ASCVD) risk. Part 2 examines goals of lipid-altering therapy to reduce ASCVD events. Both parts 1 and 2 include the author's perspective on sentinel topics. In general, some guidelines and recommendations differ with regard to ASCVD risk assessment and lipid treatment goals. However, lipid guidelines and recommendations have significant concordance regarding the need to reduce atherogenic lipoprotein cholesterol levels, and are in general agreement on the primary lipid treatment targets. Finally, a substantial degree of agreement exists among guidelines and recommendations in their emphasis on the need for aggressive treatment of hypercholesterolemia, for which the predominance of ASCVD outcomes studies suggests statins as the first-line treatment of choice. (C) 2016 National Lipid Association. All rights reserved.
引用
收藏
页码:228 / 239
页数:12
相关论文
共 63 条
  • [1] 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
    Anderson, Todd J.
    Gregoire, Jean
    Hegele, Robert A.
    Couture, Patrick
    Mancini, G. B. John
    McPherson, Ruth
    Francis, Gordon A.
    Poirier, Paul
    Lau, David C.
    Grover, Steven
    Genest, Jacques, Jr.
    Carpentier, Andre C.
    Dufour, Robert
    Gupta, Milan
    Ward, Richard
    Leiter, Lawrence A.
    Lonn, Eva
    Ng, Dominic S.
    Pearson, Glen J.
    Yates, Gillian M.
    Stone, James A.
    Ur, Ehud
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (02) : 151 - 167
  • [2] Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study
    Assmann, G.
    Schulte, H.
    Cullen, P.
    Seedorf, U.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (12) : 925 - 932
  • [3] Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study
    Assmann, G
    Cullen, P
    Schulte, H
    [J]. CIRCULATION, 2002, 105 (03) : 310 - 315
  • [4] National Lipid Association Annual Summary of Clinical Lipidology 2015
    Bays, Harold E.
    Jones, Peter H.
    Brown, W. Virgil
    Jacobson, Terry A.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) : S1 - S36
  • [5] Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association
    Bays, Harold E.
    Toth, Peter P.
    Kris-Etherton, Penny M.
    Abate, Nicola
    Aronne, Louis J.
    Brown, W. Virgil
    Gonzalez-Campoy, J. Michael
    Jones, Steven R.
    Kumar, Rekha
    La Forge, Ralph
    Samuel, Varman T.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (04) : 304 - 383
  • [6] Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
    Boekholdt, S. Matthijs
    Arsenault, Benoit J.
    Mora, Samia
    Pedersen, Terje R.
    LaRosa, John C.
    Nestel, Paul J.
    Simes, R. John
    Durrington, Paul
    Hitman, Graham A.
    Welch, K. M. A.
    DeMicco, David A.
    Zwinderman, Aeilko H.
    Clearfield, Michael B.
    Downs, John R.
    Tonkin, Andrew M.
    Colhoun, Helen M.
    Gotto, Antonio M., Jr.
    Ridker, Paul M.
    Kastelein, John J. P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (12): : 1302 - 1309
  • [7] JCL Roundtable: Lipid-lowering drugs in those older than 75 years of age
    Brown, W. Virgil
    Bittner, Vera A.
    McKenney, James M.
    Ziajka, Paul E.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) : 533 - 541
  • [8] SERUM-CHOLESTEROL CONCENTRATION AND CORONARY HEART-DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS
    CHEN, ZM
    PETO, R
    COLLINS, R
    MACMAHON, S
    LU, JR
    LI, WX
    [J]. BRITISH MEDICAL JOURNAL, 1991, 303 (6797) : 276 - 282
  • [9] CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36
  • [10] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC
    Boerwinkle, E
    Mosley, TH
    Hobbs, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) : 1264 - 1272